Drug Combo Shows Benefits in Rare, Aggressive Kidney Cancer

By News Health
5 hours Ago

(MedPage Today) — The combination of investigational sintilimab with axitinib (Inlyta) showed promise in patients with fumarate hydratase (FH)-deficient renal cell carcinoma (RCC), according to a phase II nonrandomized trial in China.
Among 41…

Source link : https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/117022

Author :

Publish date : 2025-08-15 18:21:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Trump Tax Law Could Cause Medicare Cuts if Congress Doesn't Act, CBO Says

First Therapy Approved for HPV-Related Respiratory Disease

Removing Duplicate Enrollees From Medicaid, ACA Plans Is Not as Easy as You'd Think

Excess Health Risks Linger in Childhood Cancer Survivors Into 50s and Beyond

'Forever Chemicals' May Blunt Bariatric Surgery Efficacy

Bad Diets, Too Many Meds, No Exercise: A Look Inside the Latest MAHA Report